Department of Medicine, University of California San Diego, San Diego, CA, USA.
Clinical and Translational Fungal Research Group, University of California San Diego, San Diego, CA, USA.
Mycoses. 2020 May;63(5):437-442. doi: 10.1111/myc.13067. Epub 2020 Apr 15.
Invasive fungal infections caused by Lomentospora prolificans are associated with very high mortality rates and can be challenging to treat given pan-drug resistance to available antifungal agents. The objective of this study was to describe the clinical presentation and outcomes in a cohort of patients with invasive L prolificans infections.
We performed a retrospective review of medical records of patients with invasive L prolificans infection in the FungiScope registry of rare invasive fungal infections. Patients diagnosed between 01 January 2008 and 09 September 2019 were included in for analysis.
The analysis included 41 patients with invasive L prolificans infection from eight different countries. Haematological/oncological malignancies were the most frequent underlying disease (66%), disseminated infection was frequent (61%), and the lung was the most commonly involved organ (44%). Most infections (59%) were breakthrough infections. Progression/deterioration/treatment failure was observed in 23/40 (58%) of patients receiving antifungal therapy. In total, 21/41 (51%) patients, and 77% of patients with underlying haematological/oncological malignancy, had a fatal outcome attributed to invasive fungal infection. Combination antifungal therapy was frequent (24/40) and associated with improved survival. In particular, treatment regimens including terbinafine were significantly associated with higher treatment success at final assessment (P = .012), with a positive trend observed for treatment regimens that included voriconazole (P = .054).
Lomentospora prolificans infections were associated with mortality rates of 77% and above in patients with underlying haematological/oncological malignancies and those with disseminated infections. While combination therapy is the preferred option for now, the hope lies with novel antifungals currently under development.
由繁茂枝霉引起的侵袭性真菌感染与非常高的死亡率相关,并且由于对现有抗真菌药物普遍存在泛耐药性,治疗极具挑战性。本研究的目的是描述侵袭性繁茂枝霉感染患者的临床特征和结局。
我们对罕见侵袭性真菌感染真菌学研究(FungiScope)登记处中患有侵袭性繁茂枝霉感染的患者的病历进行了回顾性分析。将 2008 年 1 月 1 日至 2019 年 9 月 9 日期间确诊的患者纳入本分析。
本分析纳入了来自八个不同国家的 41 例侵袭性繁茂枝霉感染患者。血液/肿瘤恶性肿瘤是最常见的基础疾病(66%),播散性感染很常见(61%),肺部是最常受累的器官(44%)。大多数感染(59%)为突破感染。接受抗真菌治疗的 40 例患者中有 23 例(58%)出现病情进展/恶化/治疗失败。共有 21/41(51%)例患者,以及 77%的血液/肿瘤恶性肿瘤基础疾病患者,因侵袭性真菌感染而死亡。联合抗真菌治疗较为常见(24/40),且与生存改善相关。特别是,在最终评估时,包含特比萘芬的治疗方案与更高的治疗成功率显著相关(P=0.012),包含伏立康唑的治疗方案也有治疗成功率提高的趋势(P=0.054)。
在血液/肿瘤恶性肿瘤基础疾病患者和播散性感染患者中,繁茂枝霉感染的死亡率为 77%及以上。虽然联合治疗目前是首选方案,但希望在于目前正在开发的新型抗真菌药物。